ERBB2 and osteosarcoma: In 1996, Onda et al first suggested that overexpression of HER-2 in osteosarcoma at diagnosis was associated with reduced survival.[7] Unexpectedly, Akatsuka et al in 2002 proposed a correlation between overexpression of HER-2 and better outcome for osteosarcoma.[25] Numerous subsequent studies reported contradictory results for both the expression status and prognostic value of HER-2.